Berberine ursodeoxycholate( —— )

Catalog No. M36122 CAS No. 1868138-66-2

Berberine ursodeoxycholate (HTD1801) is an orally effective hypolipidemic agent, an ionic salt of Berberine and Ursodeoxycholic acid.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	49	Get Quote
5MG	69	Get Quote
10MG	112	Get Quote
25MG	218	Get Quote
50MG	348	Get Quote
100MG	512	Get Quote
500MG	1071	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Berberine ursodeoxycholate
Note

Research use only, not for human use.
Brief Description

Berberine ursodeoxycholate (HTD1801) is an orally effective hypolipidemic agent, an ionic salt of Berberine and Ursodeoxycholic acid.
Description

Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes.
In Vitro

——
In Vivo

Berberine ursodeoxycholate shows significant reductions in HbA1c (hemoglobin A1c) levels, mean HbA1c levels decreases by 0.6%.Berberine ursodeoxycholate is ingested in the form of a salt and it is thought that the salt promptly dissociates within the gastrointestinal tract and that Berberine and Ursodeoxycholic acid are differentially absorbed.
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

1868138-66-2
Formula Weight

217.69
Molecular Formula

C6H8CuN3O2
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 5 mg/mL (6.87 mM; Ultrasonic (<60°C)
SMILES

COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC.[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC([O-])=O
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Harrison SA, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021 Sep 17;12(1):5503.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks